Compare MCFT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | JSPR |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.7M | 26.3M |
| IPO Year | 2015 | 2019 |
| Metric | MCFT | JSPR |
|---|---|---|
| Price | $19.62 | $0.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $24.25 | $15.50 |
| AVG Volume (30 Days) | 235.6K | ★ 448.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,903,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.77 | N/A |
| 52 Week Low | $17.19 | $0.32 |
| 52 Week High | $28.44 | $2.69 |
| Indicator | MCFT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 41.43 |
| Support Level | $19.15 | $0.55 |
| Resistance Level | $25.52 | $1.01 |
| Average True Range (ATR) | 1.14 | 0.06 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 11.23 | 28.89 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.